New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
08:01 EDTIPXL, SHPGImpax, Shire settle litigation on supply of authorized generic Adderall XR
Impax Laboratories (IPXL) announced that it has settled all pending litigation with Shire LLC (SHPG) and Shire Laboratories, Inc.relating to supply of its authorized generic Adderall XR under the partiesí License and Distribution Agreement that was signed in January 2006. As part of the settlement, the parties will submit a stipulation of dismissal for entry by the Court. Shire has agreed to make a one-time cash payment to Impax of $48M upon the courtís order of dismissal. The parties have entered into an amended License and Distribution Agreement which will govern the future supply of authorized generic Adderall XR from Shire to Impax. Following the end of the supply term on September 30, 2014, Impax will continue to have the right to sell its products on hand or owed to it under the agreement until depleted and will continue to pay a profit share to Shire on sales of such products. Impax will continue to pursue approval of its pending Abbreviated New Drug Application for generic Adderall XR which was filed with the U.S. Food and Drug Administration in September 2003.
News For IPXL;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
07:37 EDTSHPGPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 15, 2015
11:08 EDTSHPGOmega Advisors gives quarterly update on stakes
NEW STAKES: Targa Resources (TRGP), Targa Resources Partners (NGLS), Humana (HUM), Dow Chemical (DOW), and Twenty-First Century Fox (FOXA). INCREASED STAKES: Kinder Morgan (KMI), Chimera Investment Corporation (CIM), AerCap Holdings (AER), Shire (SHPG), and KKR & Co. (KKR). DECREASED STAKES: eBay (EBAY), Altisource Portfolio Solutions (ASPS), Caesars Entertainment (CZR), Navient (NAVI), and TerraForm Power (TERP). LIQUIDATED STAKES: HCA Holdings (HCA), Gilead (GILD), Cabot Oil & Gas (COG), and Apple (AAPL).
May 12, 2015
07:52 EDTSHPGLeerink to hold a tour
Subscribe for More Information
May 11, 2015
19:15 EDTIPXLOn The Fly: After Hours Movers
Subscribe for More Information
16:43 EDTIPXLImpax performs GMP, pre-approval inspections of Impax Hayward facility
Subscribe for More Information
16:15 EDTIPXLImpax says FDA issued Form 483 after facility inspection
Subscribe for More Information
16:14 EDTIPXLImpax reaffirms outlook for 2015
Impax still sees 2015 adjusted gross margins as a percent of total revenue are expected to be in the mid 50% range, adjusted total research and development expenses across the generic and brand divisions of $80M-$85M and capital expenditures of $45M-$50M.
16:13 EDTIPXLImpax reports Q1 adjusted EPS 9c, consensus 18c
Reports Q1 revenue $143.1M, consensus $146.13M. The company said, "This quarter's revenues were negatively impacted by the later than anticipated close of the Tower acquisition, the delayed launch of lamotrigine ODT, which was launched in April due to delayed receipt of inventory from our supplier, and the deferred recognition of product sales from the launch of RYTARY. In addition, product sales mix in the combined portfolio as well as costs related to successfully launching RYTARY and the financing of the Tower acquisition led to a reduction in our first quarter earnings."
15:00 EDTIPXLNotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use